A Restorative Approach to IOP Control

Both SLT and ABiC™ work to control IOP by a process of restoration of the natural outflow pathways. This is in contrast to traditional glaucoma surgeries and other MIGS procedures, which attempt to mechanically change or bypass the pathway of aqueous outflow. SLT stimulates a process of cellular regeneration to create a healthier, more porous trabeculasr meshwork (TM) structure, while ABiC™ flushes out the natural outflow channels, without damaging tissue and without leaving behind a stent or shunt.

SLT: First-Line, Second Line and Beyond

A simple in-office procedure, selective laser trabeculoplasty (SLT) has been shown to lower IOP as effectively as medication, and to offer a consistent safety profile. Best of all, it is efficacious at every stage of the glaucoma treatment algorithm. A highly effective primary therapy option, especially in non-compliant patients, SLT can also reduce the number of medications required to control IOP. On average, SLT achieves a reduction in IOP of 30% when used as a first-line option.

“SLT has the potential to become the go-to glaucoma treatment. Perhaps most exciting are the findings from both published studies and surgical experiences which show that SLT is as an effective alternative to medications in patients with newly-diagnosed glaucoma. Therefore, not only can SLT eliminate or at least reduce the need for expensive and inconvenient eye drops, it can help to preserve vision and delay or even prevent complicated, invasive surgical interventions.”

Savak Teymoorian, MD, MBA
Cataract and glaucoma specialist at Harvard Eye Associates, California

SLT Snapshot
  • SLT is a therapy and not a surgical treatment – it is gentle, does not destroy tissue and can be repeated.
  • SLT can lower IOP as effectively as medication.
  • SLT is a highly effective first-line therapy, and is particularly well suited to patients who are known to be non-compliant with medication (due to problems of literacy, lifestyle and mental or physical challenges)
  • SLT can be used as a replacement treatment if medication is not well tolerated.
  • SLT is a highly effective adjunct treatment in combination with medications.
  • At least one in three glaucoma patients will benefit from SLT.
  • SLT is not argon laser trabeculoplasty (ALT), which causes permanent damage to the structure of the TM.




Download SLT E-Book

ABiC: A Truly Comprehensive MIGS

Ab-interno canaloplasty (ABiC) is a new Minimally-Invasive Glaucoma Surgery (MIGS) procedure that can comprehensively restore the natural outflow pathways in glaucoma patients. In contrast to other MIGS procedures, which treat only one aspect of aqueous outflow, ABiC™ successfully and comprehensively addresses all aspects of potential outflow resistance and is designed to access, catheterize and viscodilate the trabecular meshwork, Schlemm canal and the distal outflow system, beginning with the collector channels. During the ab-interno MIGS procedure, ABiC™ utilizes a process of viscodilation of Schlemm’s canal to flush out the natural outflow channels, without damaging tissue and without leaving behind a stent or shunt – achieving an average reduction in mean IOP of 30%, combined with a 50% reduction in medication burden.*

“Rather than trying to mechanically change or bypass the pathway of aqueous outflow, ABiC acts to restore the natural outflow process by targeting all aspects of the outflow system. That is, the trabecular meshwork, Schlemm canal, and the collector channels. This is an important distinction of the procedure—especially considering that it is not always understood where the point of maximum resistance lies. It therefore makes sense to apply a procedure that comprehensively addresses the entire outflow system.”

Mark J. Gallardo, MD
El Paso Eye Surgeons, Texas, USA

ABiC Snapshot
    1. Comprehensive: treats trabecular meshwork, Schlemm’s canal and the collector channels
    2. Opens the outflow system behind the trabecular meshwork, thus ensuring better aqueous outflow
    3. Effective as both a stand-alone procedure and as a combined procedure
    4. The only MIGS indicated for use outside cataract surgery in the USA
    5. Preserves tissue and does not require permanent placement of an implant or stent
    6. On label – patient does not have to pay additionally out of pocket
    7. Minimal complications/side effects
    8. On average ABiC™ achieve a 30% reduction in mean IOP, combined with a 50% reduction in medication burden.

*228-eye ABiC 12-Month Case Series Data, presented at ASCRS 2016. Data on file. Ellex Medical.